tbuckley/cabot-search huggingface dataset:
PTH-045 Do Non-Targeted Gastric Biopsies Affect Patient Management, and Can Education and Protocol Reduce The Rate of Non-Targeted Biopsies?: Abstract PTH-045 Table 1
Authors: V Gibson, S Needham, M Nayar, N Thompson
Journal: Gut (2016)

<h3>Introduction</h3> We have previously shown that non-targeted gastric biopsies seldom contributed to patient management. We developed a local protocol for indications for gastric biopsy, which was distributed to endoscopy theatres trust-wide, and provided education via presentation of results, followed by re-audit. <h3>Methods</h3> We retrospectively analysed all gastric biopsies taken within a 3 month period in 2015, across 2 sites within Newcastle, using our histopathology and endoscopy databases. This included patient demographics, endoscopy findings, grade of endoscopist, biopsy result, and whether urease-based Helicobacter test (UBHT) was performed and the outcome. We accessed patients electronic medical records to determine whether the result of the biopsy altered diagnosis or management. We compared this to the results from our identical audit undertaken in 2013. A targeted biopsy was defined as the presence at OGD of a polyp, ulcer or any other lesion. Non-targeted biopsy was any other appearance, including gastritis. The cost of a biopsy included manpower and histopathology processing costs. We looked separately at the cost of UBHT testing plus forceps use. <h3>Results</h3> The table below compares outcomes for the 2 cycles of audit. χ<sup>2</sup>testing showed a significant reduction in the proportion of non targeted biopsies from 2013 to 2015 (p = 0.001). Of non-targeted biopsies in 2015, 0.07% (n = 1) showed lymphoma in a patient under surveillance. In 2013, 0.8% (n = 2) revealed adenocarcinoma; both biopsies from the same patient under surveillance for gastric carcinoma. No other serious diagnosis was made. Of non-targeted biopsies in 2013, 94% (n = 223) had no management alteration based on histology compared with 90% (n = 135) in 2015. Aside from patients under cancer surveillance, histology results leading to management alteration were based on presence of Helicobacter. The proportion of non targeted biopsies taken by nurse endoscopists reduced from 55% to 43%, and by SpRs, 44% to 28%. The development of a protocol appears to have led to a 36% reduction in non-targeted biopsies. This results in an annual saving of £36,432 (assuming single biopsy set cost of £103.51). <h3>Conclusion</h3> The majority of non-targeted gastric biopsies taken for histology do not contribute to the management of patients who are not under cancer surveillance. Limiting these biopsies can save significant resources. Education techniques with use of protocol can safely reduce the numbers of non-targeted biopsies. Reinforcement of this message would be expected to further reduce the rate of non-targeted biopsies. <h3>Disclosure of Interest</h3> None Declared
Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth
Authors: Taro Hitosugi, Sumin Kang, Matthew Vander Heiden, Tea-wook Chung, Shannon Elf, Katherine Lythgoe, Shaozhong Dong, Sagar Lonial, Xu Wang, Georgia Chen, Jianxin Xie, Ting-Lei Gu, Roberto Polakiewicz, Johannes L. Roesel, Titus Boggon, Fadlo Khuri, D. Gary Gilliland, Lewis Cantley, Jonathan L. Kaufman, Jing Chen
Journal: Blood (2010)
The Experience of Gruppo Laziale for the Study of Ph-, Chronic Myeloproliferative Syndromes in the Treatment of Myeloproliferative Neoplasms in Blastic Phase with Azacytidine
Authors: Alessandro Andriani, Marco Montanaro, Maria Teresa Voso, Nicoletta Villivà, Fabrizio Ciccone, Cristina Andrizzi, Cinzia De Gregoris, Francesco Buccisano, Giuliana Alimena, Roberto Latagliata
Journal: Blood (2014)
Monoubiquitination of the Fanconi Anemia D2 (FANCD2) Protein Regulates the Transforming Potential of BCR/ABL
Authors: Mateusz Koptyra, Tomasz Stoklosa, Grazyna Hoser, Ilona Seferynska, Eliza Glodkowska, Tomasz Skorski
Journal: Blood (2008)
FRI0084 Clinical, Ultrasonographic and Immunologic Biomarkers of Ramris Progression in RA Patients in Clinical Remission: A Prospective Study of 12 Months of Follow-Up: Table 1.
Authors: J. Ramírez, J.A. Narvaez, V. Ruiz-Esquide, J. Hernández, R. Celis, A. Cuervo, M.V. Hernández, J. Inciarte-Mundo, R. Sanmartí, J.D. Cañete
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> A high proportion of patients with rheumatoid arthritis (RA) in clinical remission (CR) present subclinical synovitis when evaluated by sonography. Most prospective studies on baseline biomarkers of radiographic progression in this patients not include immunological biomarkers that could be of interest to better identify the residual inflammatory activity. <h3>Objectives</h3> To determine clinical, serological and ultrasonografic variables predicting progression of structural damage as evaluated by MRI at 12 months (mo.) of follow-up in a cohort of RA patients in CR. <h3>Methods</h3> We included 42 RA patients in CR defined as DAS28-ESR&lt;2.6 for &gt;6 mo. Complete clinical and biological assessment, ultrasonography of two hands and MRI of dominant hand were performed at baseline and after 12 mo. We analyzed risk factors related with RAMRIS progression with multivariate lineal models. <h3>Results</h3> 42 patients were included (76.7% female). Mean age was 53.5 years, body mass index (BMI) 26.7 kg/m<sup>2</sup>. Disease and remission median duration were 94 and 37 mo. respectively. 73.8% RF[+] patients and 85.7% ACPA [+]. RAMRIS 10.3 and erosion (RAMRIS) 18.8. At baseline, 66.7% had power-doppler (PD) signal and 45.2% also had synovial hyperplasia grade ≥2, so fulfilling the criteria of previously defined ultrasound defined active synovitis (UdAS)<sup>1</sup>. The risk factors more related with RAMRIS progression at 12 mo. were baseline RAMRIS, BMI, disease duration, low-dose prednisone treatment, absence of csDMARDs treatment and presence of UdAS. Synovitis as defined by only PD positive signal was no associated to erosions. We excluded the baseline RAMRIS in the multivariate model because it was the strongest predictor factor. We observed that higher serum levels of calprotectin and ENA78 at baseline were significant predictors. Absence of csDMARD treatment, disease duration and the presence of UdAS also remained as independent predictive factors (Table 1). <h3>Conclusions</h3> This prospective study confirms a high prevalence of UdAS in patients with RA in CR, which is an independent risk factor to develop structural damage progression at 12 months of follow-up. Baseline RAMRIS, BMI, disease duration, absence of csDMARDs therapy, UdAS, and baseline levels of calprotectin and ENA78, were independent predictors of RAMRIS progression. <h3>References</h3> Ramírez J, et al. Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers. Arthritis Res Ther. 2014;16(1):R5 <h3>Disclosure of Interest</h3> None declared
A Bone Marrow Population Containing Both Hematopoietic and Mesenchymal Stem Cells Constitutively Expressing Genes Pairs For: SDF1-CXCR4, CX3CL-CXCR1 and for VEGF Improves Vascularization When Implanted to Ischemic Legs.
Authors: A. Lange, W. Witkiewicz, D. Dlubek, L. Maslowski, D. Drabczak-Skrzypek, E. Jaskula, B. Szymczak, D. Duda, J. Lange
Journal: Blood (2004)
Reply: ‘More viral mutants, less HBsAg clearance? One size may not fit all'
Authors: Alex Thompson, Stephen Locarnini, Peter Revill
Journal: Gut (2016)

We thank Dr Tseng and colleagues for their interest1 in our recent study that identified a negative association between the presence of hepatitis B virus (HBV) basal core promoter (BCP)/precore (PC) and precore (PC) variants mutants at baseline and lower likelihood of hepatitis B surface antigen (HBsAg) loss among 157 subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) treated for 4 years with tenofovir therapy. 2–4 The likelihood of HBsAg loss was 41% in subjects with wild-type (WT) sequence at the BCP/PC loci versus 3% in subjects with detectable BCP/PC variants (next generation sequencing (NGS), Illumina MiSeq—threshold for detection >1%). The cohort included subjects with a broad range of HBV genotypes (genotype A, n=36 (23%); genotype B, n=24 (15%); genotype C, n=51 (32%) and …
A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER
Authors: Ryan Hunt, Ayla Yalamanoglu, James Tumlin, Tal Schiller, Jin Hyen Baek, Andrew Wu, Agnes B. Fogo, Haichun Yang, Edward Wong, Peter Miller, Paul W. Buehler, Chava Kimchi-Sarfaty
Journal: Blood (2016)
Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies
Authors: Luciano J. Costa, Kami Maddocks, Narendranath Epperla, Nishitha M. Reddy, Reem Karmali, Elvira Umyarova, Veronika Bachanova, Cristiana Costa, Martha J. Glenn, Julio C. Chavez, Oscar Calzada, Frederick Lansigan, Hossain Nasheed, Stefan K. Barta, Zheng Zhou, Michael Jaglal, Saurabh Chhabra, Francisco Hernandez‐Ilizaliturri, Ana C. Xavier, Amitkumar Mehta, Deniz Peker, Andreas Forero‐Torres, Zeina Al‐Mansour, Andrew M. Evens, Jonathon B. Cohen, Christopher R. Flowers, Timothy S. Fenske, Mehdi Hamadani
Journal: American Journal of Hematology (2016)

The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse < 6 months from end of therapy (early relapse; ER). Median age was 58 years and response to salvage was 41.7%. Two-year OS was 18.5% in PP, 30.6% in RD and 45.5% in ER. The presence of PP, intermediate-high/high NCCN-IPI at time of PTF or MYC translocation predicted 2-year OS of 13.6% constituting ultra-high risk (UHR) features. Among the 132 patients who underwent autologous hematopoietic cell transplantation, 2-year OS was 74.3%, 59.6% and 10.7% for patients with 0,1 and 2-3 UHR features respectively. Patients with PTF and UHR features should be prioritized for clinical trials with newer agents and innovative cellular therapy.
AB0468 Caracteristics of Renal Involvement in Patients with Primary Sjögren's Syndrome
Authors: L. Belhaj, A. Hariz, I. Boukhris, S. Azzabi, E. Cherif, I. Kechaou, L. Ben Hassine, N. Khalfallah
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Renal involvement is one of the most common manifestations of primary Sjögren9s syndrome (pSS) and has no specific symptoms. <h3>Objectives</h3> - Identify the clinical and biological characteristics of patients with renal involvement in pSS. - Identify the immunological profile of these patients. - Specify the adequate treatment. <h3>Methods</h3> Fourty five patients with pSS admitted inCharles Nicolleuniversity Hospital from 2005 to 2015 were enrolled. All the patients met the validated European-American co-criteria of 2002 for pSS. No patients with secondary SS were included. <h3>Results</h3> Fourty five patients were enrolled in our study. Nine of them had renal involvement: eight women and 1 man. The mean age was 44,5 years. Time from onset to diagnosis was about 2,33 years. Concerning the kidney damage, 4 of the patients developed renal tubular acidosis (RTA), 3 of them developed others tubulo-interstitial disorders and 2 were diagnosed with glomerular disorder withhigh proteinuria. One of the nine patients had diabetis insipidus. Laboratory examinations showed 3 cases of hyperchloremia and 6 cases of hypokaliemia. One patient had hypokaliemic paralysis. Six patients had creatinincleranceunder 50 ml/mn. All patients received symptomatic treatment. Seven patients were treated with corticosteroids and 3 patients received hydroxylchloroquine. <h3>Conclusions</h3> Patients with pSS commonly present with renal impairment.Tubular disorders are the main renal involvementespecially RTA. Glomerular lesions might be predominant. Morbidity of chronic renal failure might account for a certain proportion of pSS. Corticosteroids therapy might improve the prognosis. <h3>References</h3> Vitali C, Tavoni A, Sciuto M, Maccheroni M, Moriconi L, Bombardieri S. Renal involvement in primary Sjögren9s syndrome: a retrospective-prospective study. Scand J Rheumatol 1991;20:132–6. Bossini N, Savoldi S, Franceschini F, et al. Clinical and morphological features of kidney involvement in primary Sjogren9s syndrome.Nephrol Dial Transplant 2001;16:2328–36 Rayadurg J, Koch AE. Renal insufficiency from interstitial nephritis in primary Sjögren9s syndrome. J Rheumatol 1990;17:1714–8. Viergever PP, Swaak TJ. Renal tubular dysfunction in primary Sjögren9s syndrome: clinical studies in 27 patients. ClinRheumatol 1991;10:23–7. <h3>Disclosure of Interest</h3> None declared
PTU-035 Sphincterotomy in Periampullary Duodenal Diverticulum
Authors: S Mogan, R tighe
Journal: Gut (2016)

<h3>Introduction</h3> Periampullary duodenal diverticulum (PAD) was first described by J. Chomel in 1710.<sup>1</sup> The pathophysiological mechanism of occurrence may include both traction and pulsion. Incidence widely varies between 7%–32% of the patients at the time of endoscopic retrograde cholangiopancreatography (ERCP).<sup>2</sup> There is conflicting data on cannulation rates and Post ERCP complications in patients with PAD. <h3>Methods</h3> We conducted a retrospective review on the data of all patients who underwent a sphincterotomy in the presence of Periampullary diverticulum between Jan 2007 and Aug 2015. Comprehensive information was gathered with regards to patient’s demographics, procedural indications and procedure success rates. We assessed the cannulation rates, complications and number of procedures required to clear stones during the first ERCP. <h3>Results</h3> 389 patients with periampullary diverticulum who underwent sphincterotomy were identified and analysed during this period. The incidence of PAD was 13.2%. 54% were females and the mean age was 74 years (range, 35–100 years). 257 patients (66%) were above the age of 65. The most common underlying diagnoses were Common bile duct (CBD) stones (74%) and Cholangiocarcinoma (12%) followed by Chronic Pancreatitis (6%), Bile leak (2%) and Pancreatic cancer (2%). Other indications were Sphincter of oddi dysfunction, Primary sclerosing cholangitis and IgG4 related cholnagiopathy (4%). Successful cannulation was achieved in 359 patients (92%). 60 patients (15%) needed at least two procedures for successful stone clearance. Successful stone clearance was achieved in 227 patients (79%) of patients with CBD stones. 16 patients (5%) with CBD stones needed more than two ERCP procedures to achieve stone clearance. Combined endoscopic (rendezvous) and percutaneous approach was needed in 12 patients (3%). 11 patients developed post ERCP Pancreatitis (3%). 3 patients (0.84%) had retroperitoneal perforation post sphincterotomy. 8 patients (2%) had moderate to severe post sphincterotomy bleeding requiring transfusion or endoscopic/angiographic intervention. There were no reported cases of procedure related mortality. <h3>Conclusion</h3> Endoscopic sphincterotomy is safe in this cohort given the right indication. An other safe adjunct is balloon sphincteroplasty. We did not see any significant increase in Post ERCP mortality or morbidity comparing with national standards. The finding of PAD had no effect on successful cannulation. <h3>References</h3> 1 Chomel JB.<i> The Royal Academy of History, Paris</i>. Paris: The Institute France, Academy of Sciences; 1710. p. 37. 2 Tyagi P, Sharma P, Sharma BC, Puri AS. Periampullary diverticula and technical success of endoscopic retrograde cholangiopancreatography. <i>Surg Endosc</i> 2009;<b>23</b>:1342–5. <h3>Disclosure of Interest</h3> None Declared
Cytidine Deaminase Genotype Modifies the Toxicity of Therapy for Childhood AML.
Authors: Deepika Bhatla, Robert B. Gerbing, Heather D. Conner, Todd A. Alonzo, Xiaowen Zhai, Parinda Mehta, Julie A. Ross, Hartmut Geiger, Beverly J. Lange, John P. Perentesis, Stella M. Davies
Journal: Blood (2006)
Three Steps to Improve Management of Noncommunicable Diseases in Humanitarian Crises
Authors: Kiran Jobanputra, Philippa Boulle, Bayard Roberts, Pablo Perel
Journal: PLoS Medicine (2016)

Kiran Jobanputra and colleagues argue that better evidence, guidance, and tools are needed to improve the effectiveness and feasibility of noncommunicable disease care in humanitarian settings.
Rosacea treatment update: recommendations from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus ( <scp>ROSCO</scp> ) panel
Authors: M. Schaller, L.M.C. Almeida, A. Bewley, B. Cribier, N.C. Dlova, G. Kautz, M. Mannis, H.H. Oon, M. Rajagopalan, M. Steinhoff, D. Thiboutot, P. Troielli, G. Webster, Y. Wu, E. Zuuren, J. Tan
Journal: British Journal of Dermatology (2016)

Rosacea is currently treated according to subtypes. As this does not adequately address the spectrum of clinical presentation (phenotypes), it has implications for patient management. The ROSacea COnsensus panel was established to address this issue. To incorporate current best treatment evidence with clinical experience from an international expert panel and establish consensus to improve outcomes for patients with rosacea. Seventeen dermatologists and three ophthalmologists reached consensus on critical aspects of rosacea treatment and management using a modified Delphi approach. The panel voted on statements using the responses 'strongly disagree', 'disagree', 'agree' or 'strongly agree'. Consensus was defined as ≥ 75% 'agree' or 'strongly agree'. All voting was electronic and blinded. The panel agreed on phenotype‐based treatments for signs and symptoms presenting in individuals with rosacea. First‐line treatments were identified for individual major features of transient and persistent erythema, inflammatory papules/pustules, telangiectasia and phyma, underpinned by general skincare measures. Multiple features in an individual patient can be simultaneously treated with multiple agents. If treatment is inadequate given appropriate duration, another first‐line option or the addition of another first‐line agent should be considered. Maintenance treatment depends on treatment modality and patient preferences. Ophthalmological referral for all but the mildest ocular features should be considered. Lid hygiene and artificial tears in addition to medications are used to treat ocular rosacea. Rosacea diagnosis and treatment should be based on clinical presentation. Consensus was achieved to support this approach for rosacea treatment strategies.
Biological Effects of External Beta Radiation
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SP0025 Complement Deficiencies and Rheumatic Diseases
Authors: L. Trouw
Journal: Annals of the Rheumatic Diseases (2016)

The complement system is an integral part of both the innate and adaptive immune responses. Although a wealth of insight into the function of the different complement proteins has been obtained by biochemical studies, real insight into the overall role of complement and specific complement proteins has been obtained by studying the rare cases of complete genetic deficiency observed in the human population. The detailed analyses of the clinical manifestations of persons genetically deficient for complement proteins identified some obvious aspects, but also several rather remarkable ones. For example the genetic deficiency of circulating C3 led to increased risk for several types of bacterial infections, but deficiency in C9, an essential component of the membrane attack complex (MAC) required for lysis did only predispose to one particular type of infections; with <i>Neisseria</i>. These data indicate that complement is involved in the immune defence against infections via C3, but that lysis by the MAC is except for <i>Neisseria</i> not so relevant. One other remarkable observations was the association between genetic deficiency for classical pathway complement proteins with autoimmunity, especially systemic lupus erythematosus (SLE). Sspecially striking is the observation that there is a hierarchy, within the pathway, with C1q being the strongest associated with SLE, followed by C4 and C2 with almost no association with C3 deficiency. How deficiency of classical pathway proteins contributes is not yet clear but seems to be the result of an interplay between decreased clearance of dead cells and an altered adaptive immune activation threshold. Recently we identified a new case of complete C1q deficiency and this child did not display signs of SLE (yet). We were struck by the absence of reports on follow-up data of the cases with reported C1q deficiency and conducted a questionnaire based study. From this study we could conclude that there is enormous variation in the severity of clinical symptoms between persons, with some being very affected leading to premature death and other individuals, sometimes from the same family, seemingly completely unaffected. These findings are relevant also in view of the developments of therapy as now haematopoietic stem cell transplantation (HSCT) has become a feasible option to treat such individuals. In this context we argue for a well-balanced evaluation of the pro9s and con9s of such treatment modalities in view of the variation in clinical symptoms and severity observed in these individuals. <h3>Disclosure of Interest</h3> None declared
The Anthropocene Biosphere: Supporting ‘Open Interdisciplinarity’ through Blogging
Authors: Zev M. Trachtenberg, Thomas J. Burns, Kirsten de Beurs, Stephen E. Ellis, Kiza K. Gates, Bruce W. Hoagland, Jeffrey F. Kelly, Thomas M. Neeson, Asa R. Randall, Ingo Schlupp, Peter S. Soppelsa, Gerilyn S. Soreghan, James J. Zeigler
Journal: Trends in Ecology & Evolution (2016)
Hematopoietic Progenitor Cell Response to SDF-1 alpha and SDF-1 alpha Production Are Impaired in Chronic Phase Chronic Myeloid Leukemia at Diagnosis.
Authors: Thomas Prebet, Kaddour Chabane, Isabelle Tigaud, Eric Wattel, Mauricette Michallet, Franck E. Nicolini
Journal: Blood (2005)
High-Dose Sequential Chemotherapy (HDS) Followed by Autologous Stem Cell Transplantation (ASCT) in Relapsing/Refractory Hodgkin Lymphoma (HL): Long-Term Results.
Authors: Andrea Gallamini, Claudia Castellino, Simonetta Viviani, Andrea Rossi, Atto Billio, Alessandro Mistretta, Marco Sorio, Angela Gueli, Alessandro Rambaldi, Sergio Cortelazzo, Caterina Patti, Fabio Benedetti, PierFederico Torchio, Alessandro M. Gianni, Corrado Tarella
Journal: Blood (2007)